WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., an innovative molecular information company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,422,594 for the Company’s Decontamination-Ready Encoded Amplification PCR (DREAM™ PCR) technology. Through its innovative approach, DREAM PCR digests any previous PCR products on a real-time basis, removing the risk that DNA from earlier tests may contaminate current or future tests involving PCR amplification in the clinical laboratory. DREAM PCR also eliminates the need for separate, isolated pre- and post-PCR setup areas, improving efficiencies by allowing labs to save space, and reducing the amount equipment and personnel required.
DREAM PCR is integrated into the sample setup process prior to performing the PCR assays. Courtagen has incorporated DREAM PCR into all of its clinical diagnostic assays for autism / developmental delay, epilepsy, and mitochondrial disorders utilizing next generation sequencing, as well into quantitative PCR (qPCR) products for testing medical cannabis safety and quality sold by Medicinal Genomics Corporation (MGC), a wholly owned subsidiary of Courtagen.
“We are thrilled that the USPTO has issued this patent for DREAM PCR”, says Kevin McKernan, Courtagen’s Chief Scientific Officer, “with clinical laboratories standardizing on universal primer sequences, it is becoming increasingly important to eliminate sources of background contamination for rare allele detection.”
In addition to its decontamination benefits, DREAM PCR can potentially improve freedom to operate with respect to the navigation of gene patents by challenging the interpretation of composition-of-matter and encoding claims. DREAM PCR also improves the accuracy of mitochondrial DNA sequencing by removing NUMT (nuclear mitochondrial DNA) contamination, and is an integral part of Courtagen’s mtSEEK mitochondrial genome sequencing test.
About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen’s work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit http://www.courtagen.com/
About Medicinal Genomics Corporation
Medicinal Genomics Corporation applies state-of-the-art life science technology to Cannabis plant genetics. Our products help growers, dispensaries, and safety testing laboratories characterize and understand the quality of medicinal cannabis. Medicinal Genomics utilizes a highly sophisticated Next Generation Sequencing laboratory, bioinformatics system, and DNA based technologies to deliver unmatched technical solutions to decipher the genetic code and quality level of medicinal Cannabis. Medicinal Genomics is a wholly owned subsidiary of Courtagen Life Sciences, Inc. For more information, please visit http://www.medicinalgenomics.com/